We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+51.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.01B
AUM Growth
+$676M
Cap. Flow
-$150M
Cap. Flow %
-4.98%
Top 10 Hldgs %
75.26%
Holding
119
New
16
Increased
18
Reduced
26
Closed
23

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$54.2M
2
SRRK icon
Scholar Rock
SRRK
+$27.3M
3
ARWR icon
Arrowhead Research
ARWR
+$27.2M
4
PRTA icon
Prothena Corp
PRTA
+$19.3M
5
KRRO icon
Korro Bio
KRRO
+$13.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.9M
3
IMGN
Immunogen Inc
IMGN
+$24M
4
FOLD
Amicus Therapeutics
FOLD
+$23.1M
5
RVMD icon
Revolution Medicines
RVMD
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 50.36%
2 Consumer Discretionary 46.45%
3 Technology 0.44%
4 Real Estate 0.13%
5 Communication Services 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$7.64B
$1.38B 45.73%
32,007,990
– –
SRRK icon
2
Scholar Rock
SRRK
$5.88B
$212M 7.04%
11,259,438
+2,199,931
+24% +$27.3M
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$1.03B
$180M 5.98%
117,553,284
– –
CYTK icon
4
Cytokinetics
CYTK
$10.8B
$101M 3.37%
1,214,284
-304,547
-20% -$11M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$85.1M 2.83%
1,421,346
-243,226
-15% -$12.3M
ONC
6
BeOne Medicines Ltd
ONC
$33.9B
$73M 2.43%
404,480
+546
+0.1% +$98.8K
KYMR icon
7
Kymera Therapeutics
KYMR
$8.65B
$64.4M 2.14%
2,530,735
+725,389
+40% +$13M
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$61.8M 2.05%
2,138,188
– –
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$59M 1.96%
1,615,348
-201,272
-11% -$5.25M
SLN
10
Silence Therapeutics
SLN
$518M
$52.1M 1.73%
3,000,000
+500,000
+20% +$5.61M
RVMD icon
11
Revolution Medicines
RVMD
$38.6B
$48.6M 1.62%
1,695,949
-833,788
-33% -$20M
ARGX icon
12
argenx
ARGX
$55.1B
$44.3M 1.47%
+116,388
New +$54.2M
NMRA icon
13
Neumora Therapeutics
NMRA
$311M
$43.5M 1.45%
2,552,702
-250,000
-9% -$3.07M
FOLD
14
CALL
DELISTED
Amicus Therapeutics
FOLD
$35.5M 1.18%
2,500,000
+2,000,000
+400% +$22.7M
ARWR icon
15
Arrowhead Research
ARWR
$12.2B
$31.5M 1.05%
1,028,255
+1,022,815
+18,802% +$27.2M
MRTX
16
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$29.4M 0.98%
500,000
-200,000
-29% -$11.2M
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$28.8M 0.96%
2,026,364
-2,036,203
-50% -$23.1M
IGMS
18
DELISTED
IGM Biosciences
IGMS
$25.8M 0.86%
3,100,422
+578,178
+23% +$3.36M
KURA icon
19
Kura Oncology
KURA
$804M
$25.4M 0.85%
1,768,056
-250,000
-12% -$2.46M
SLRN
20
DELISTED
ACELYRIN
SLRN
$22.6M 0.75%
3,035,888
+566,609
+23% +$4.84M
CBIO
21
Crescent Biopharma
CBIO
$604M
$20.3M 0.67%
85,891
– –
KRRO icon
22
Korro Bio
KRRO
$150M
$20.1M 0.67%
+418,605
New +$13.8M
SYRS
23
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$19.5M 0.65%
2,505,013
+1,029,269
+70% +$3.53M
PRTA icon
24
Prothena Corp
PRTA
$444M
$18.2M 0.61%
+501,360
New +$19.3M
DNLI icon
25
Denali Therapeutics
DNLI
$3.77B
$17.2M 0.57%
802,899
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2023 Portfolio in Review

As of Q4 2023, Artal Group held 119 positions worth $3.01B, up 29% from $2.33B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Artal Group withdrew a net $150M in Q4 2023, closing 23 positions and reducing 26 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in argenx worth $44.3M.

  • Artal Group's largest Q4 2023 buy was argenx: 116,388 shares worth $44.3M.
  • Artal Group added most to Scholar Rock in Q4 2023, an estimated $27.3M increase.
  • Artal Group's biggest Q4 2023 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $46.9M.
  • Artal Group fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $114M.
  • Artal Group's ten largest holdings make up 75% of its $3.01B portfolio in Q4 2023.
  • Artal Group opened 16 new positions and closed 23 in Q4 2023.
  • Artal Group's portfolio value rose 29% quarter-over-quarter to $3.01B.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.